Sawyer & Company Inc acquired a new position in Abbott Laboratories (NYSE:ABT) during the fourth quarter, Holdings Channel reports. The fund acquired 30,225 shares of the healthcare product maker’s stock, valued at approximately $1,725,000. Abbott Laboratories comprises 1.1% of Sawyer & Company Inc’s holdings, making the stock its 28th largest holding.

Several other institutional investors also recently bought and sold shares of ABT. Heritage Trust Co lifted its stake in Abbott Laboratories by 10.1% in the second quarter. Heritage Trust Co now owns 2,175 shares of the healthcare product maker’s stock valued at $106,000 after buying an additional 200 shares during the period. Tributary Capital Management LLC acquired a new position in Abbott Laboratories in the third quarter valued at approximately $106,000. Thompson Davis & CO. Inc. lifted its stake in Abbott Laboratories by 17.7% in the second quarter. Thompson Davis & CO. Inc. now owns 2,463 shares of the healthcare product maker’s stock valued at $120,000 after buying an additional 370 shares during the period. JFS Wealth Advisors LLC lifted its stake in Abbott Laboratories by 349.0% in the second quarter. JFS Wealth Advisors LLC now owns 2,694 shares of the healthcare product maker’s stock valued at $131,000 after buying an additional 2,094 shares during the period. Finally, Motco lifted its stake in Abbott Laboratories by 213.7% in the second quarter. Motco now owns 2,880 shares of the healthcare product maker’s stock valued at $140,000 after buying an additional 1,962 shares during the period. 71.22% of the stock is currently owned by institutional investors.

In related news, insider Daniel Gesua Sive Salvadori sold 71,157 shares of the company’s stock in a transaction on Tuesday, November 14th. The stock was sold at an average price of $55.00, for a total transaction of $3,913,635.00. Following the completion of the sale, the insider now owns 144,955 shares in the company, valued at $7,972,525. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Chairman Miles D. White sold 276,886 shares of the company’s stock in a transaction on Wednesday, December 6th. The stock was sold at an average price of $54.41, for a total value of $15,065,367.26. Following the sale, the chairman now owns 3,677,913 shares of the company’s stock, valued at approximately $200,115,246.33. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 445,615 shares of company stock valued at $24,666,341. Corporate insiders own 0.76% of the company’s stock.

Several equities analysts have issued reports on ABT shares. Bank of America boosted their price target on Abbott Laboratories from $60.00 to $70.00 in a research note on Wednesday, January 24th. They noted that the move was a valuation call. Jefferies Group reissued a “buy” rating and issued a $65.00 price target on shares of Abbott Laboratories in a research note on Thursday, October 19th. Zacks Investment Research raised Abbott Laboratories from a “hold” rating to a “buy” rating and set a $61.00 price target on the stock in a research note on Monday, October 16th. Cowen set a $68.00 price target on Abbott Laboratories and gave the company a “buy” rating in a research note on Thursday, October 19th. Finally, Stifel Nicolaus boosted their price target on Abbott Laboratories from $58.00 to $63.00 and gave the company a “buy” rating in a research note on Thursday, October 19th. Eight equities research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $65.47.

Shares of Abbott Laboratories (NYSE ABT) opened at $57.17 on Friday. The company has a market capitalization of $101,100.00, a P/E ratio of 285.85, a PEG ratio of 1.69 and a beta of 1.55. Abbott Laboratories has a 1-year low of $42.31 and a 1-year high of $64.60. The company has a current ratio of 2.69, a quick ratio of 2.26 and a debt-to-equity ratio of 0.72.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings data on Wednesday, January 24th. The healthcare product maker reported $0.74 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.73 by $0.01. The firm had revenue of $7.59 billion during the quarter, compared to the consensus estimate of $7.38 billion. Abbott Laboratories had a return on equity of 13.80% and a net margin of 1.74%. The company’s quarterly revenue was up 42.3% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.65 earnings per share. sell-side analysts expect that Abbott Laboratories will post 2.86 EPS for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, February 15th. Stockholders of record on Friday, January 12th will be issued a dividend of $0.28 per share. This is an increase from Abbott Laboratories’s previous quarterly dividend of $0.27. The ex-dividend date of this dividend is Thursday, January 11th. This represents a $1.12 annualized dividend and a dividend yield of 1.96%. Abbott Laboratories’s payout ratio is currently 560.00%.

ILLEGAL ACTIVITY NOTICE: This story was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this story on another website, it was stolen and reposted in violation of US and international copyright and trademark legislation. The legal version of this story can be read at https://www.thecerbatgem.com/2018/02/10/30225-shares-in-abbott-laboratories-abt-purchased-by-sawyer-company-inc.html.

Abbott Laboratories Profile

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT).

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.